Physician profile
Freddy Keys
NPI 1134508120
$3,971.25
in general payments reported to CMS, 2019-2025
21 companies · $2,869 in 2025
The $2,869 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.44 · 2022: $239 · 2023: $239 · 2024: $596 · 2025: $2,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,859 · Travel and Lodging: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,858.61 |
| Travel and Lodging | $845.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,434.14 | 2025 | Trintellix |
| Abbvie INC. | $763.35 | 2022-2025 | |
| Amgen INC. | $280.38 | 2024-2025 | Krystexxa, Tavneos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $264.20 | 2024-2025 | Caplyta |
| Antares Pharma, INC. | $202.88 | 2024-2025 | Xyosted |
| Novo Nordisk INC | $164.16 | 2024-2025 | Wegovy |
| Exact Sciences Corporation | $148.13 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $133.82 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $112.71 | 2021-2025 | |
| Glaxosmithkline, LLC. | $107.93 | 2024-2025 | Benlysta |
| Biohaven Pharmaceutical Holding Company Ltd. | $61.06 | 2022 | |
| Ucb, INC. | $49.32 | 2024-2025 | Bimzelx, Cimzia |
| Kiniksa Pharmaceuticals International, Plc | $48.30 | 2024 | Arcalyst |
| Sumitomo Pharma America, INC. | $37.59 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals Lp | $33.52 | 2025 | Airsupra, Breztri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $28.62 | 2024 | Rexulti |
| Ani Pharmaceuticals, INC. | $27.50 | 2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $21.36 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $21.28 | 2025 | Fanapt |
| Biohaven Pharmaceuticals, INC. | $15.82 | 2021 | |
| Horizon Therapeutics Plc | $15.18 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freddy Keys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.